0.00Open0.15Pre Close0 Volume65 Open Interest2.50Strike Price0.00Turnover95.45%IV14.86%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.2973Delta0.4991Gamma18.40Leverage Ratio-0.0047Theta-0.0006Rho-5.47Eff Leverage0.0025Vega
Eledon Pharmaceuticals Stock Discussion
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart for preventing organ rejection in kidney transplant patients at the American Transplant Congress.
The study involved 13 participants and demonstrated a consistent mean eGFR of 70.5 mL/min/1.73m² at all reported time points post-transpl...
NEWS
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
05/09/2024 - 04:00 AM
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will ...
Benzinga· 2 mins ago
Pull up Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), this company has made headlines with its announcement of securing an oversubscribed $50 million private placement. This strategic financial endeavor is not just a testament to the confidence that institutional and accredited healthcar...
Eledon Pharmaceuticals Announced A Private Investment Of Approximately $50M, With Sale Of 13.1M Shares At $2.37/Share And Pre-funded Warrants At $2.369/Underlying Share, Which Are Exercisable To Purchase 7.99M Shares
⇒ Pig to a Human
⇒ Use of Tegoprubart (anti-CD40L antibody)
⇒ Immunosuppressive treatment
$Bristol-Myers Squibb(BMY.US)$
⇒ First CAR T Cell Therapy approval in the EU
⇒ Abecma
No comment yet